Liquidation: HOOKIPA Pharma Inc.

Form Type: PREM14A

Filing Date: 2025-06-16

Corporate Action: Liquidation

Type: New

Accession Number: 000114036125022509

Filing Summary: HOOKIPA Pharma Inc. is calling a special meeting of stockholders to vote on significant corporate actions including the approval of an Asset Sale and the company's liquidation and dissolution. The Asset Sale involves selling key assets related to its Hepatitis B and HIV programs to Gilead Sciences, with shareholders required to provide a majority approval for both actions. The liquidation is contingent upon the Asset Sale's approval. The meeting will be held virtually, necessitating the participation of stockholders who will vote on these critical proposals, which are described in detail within the proxy statement. The Board of Directors recommends approval of these proposals as they believe it to be in the best interest of the company and its shareholders.